Michael M. Kitt
Directeur Général chez Axalbion Therapeutics Ltd.
Profil
Michael M.
Kitt currently works at Axalbion Therapeutics Ltd., as Chief Executive Officer.
Dr. Kitt also formerly worked at Attenua, Inc., as President, CEO, CFO & Director from 2018 to 2019, COR Therapeutics, Inc., as Vice President-Clinical Research from 1993 to 2002, The Upjohn Co., as Vice President-International Clinical Research, Portola Pharmaceuticals, Inc., as Chief Medical Officer & Senior Vice President from 2011 to 2013, Afferent Pharmaceuticals, Inc., as Chief Medical Officer, Innoviva, Inc., as Senior Vice President-Development from 2002 to 2008, Nuon Therapeutics, Inc., as Chief Medical Officer from 2008 to 2011, and Sterling Winthrop Pharmaceuticals Research Center, as Senior Vice President-Clinical Research.
Dr. Kitt received his undergraduate degree from New York University Tandon School of Engineering and doctorate degree from New York University School of Medicine.
Postes actifs de Michael M. Kitt
| Sociétés | Poste | Début |
|---|---|---|
Axalbion Therapeutics Ltd.
 Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt. | Directeur Général | - |
Anciens postes connus de Michael M. Kitt
| Sociétés | Poste | Fin |
|---|---|---|
Attenua, Inc.
 Attenua, Inc. Pharmaceuticals: MajorHealth Technology Attenua, Inc. engages in the provision of biopharmaceutical services. The company was founded by Jing Liang and is headquartered in San Mateo, CA. | Directeur Général | 01/11/2019 |
| PORTOLA PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 16/08/2013 |
Nuon Therapeutics, Inc.
 Nuon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nuon Therapeutics Inc. develops therapies to treat inflammation and neurological diseases. The company focuses on the development and commercialization of new therapies for autoimmune disease and inflammation includes rheumatoid arthritis and multiple sclerosis. Nuon Therapeutics was founded by Kim Puloma Kamdar, Marc Feldmann, Lawrence J. Steinman and Michael Selley in 2006 and is headquartered in San Mateo, CA. | Directeur Technique/Scientifique/R&D | 01/06/2011 |
| The Upjohn Co. | Directeur Technique/Scientifique/R&D | 25/02/2011 |
| INNOVIVA, INC. | Corporate Officer/Principal | 20/06/2008 |
Formation de Michael M. Kitt
| New York University Tandon School of Engineering | Undergraduate Degree |
| New York University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INNOVIVA, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Nuon Therapeutics, Inc.
Nuon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nuon Therapeutics Inc. develops therapies to treat inflammation and neurological diseases. The company focuses on the development and commercialization of new therapies for autoimmune disease and inflammation includes rheumatoid arthritis and multiple sclerosis. Nuon Therapeutics was founded by Kim Puloma Kamdar, Marc Feldmann, Lawrence J. Steinman and Michael Selley in 2006 and is headquartered in San Mateo, CA. | Health Technology |
| Sterling Winthrop Pharmaceuticals Research Center | |
| The Upjohn Co. | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Afferent Pharmaceuticals, Inc.
 Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA. | Health Technology |
Attenua, Inc.
Attenua, Inc. Pharmaceuticals: MajorHealth Technology Attenua, Inc. engages in the provision of biopharmaceutical services. The company was founded by Jing Liang and is headquartered in San Mateo, CA. | Health Technology |
Axalbion Therapeutics Ltd.
Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt. | Health Technology |
